Posted on: November 16, 2019 Posted by: earlenehands Comments: 0

Dr. Geiger on Challenges of Patients With CSCC Enrolled in KEYNOTE-630 Trial



Jessica Geiger, MD, medical oncologist, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses challenges with the patient population enrolled in the phase III KEYNOTE-630 trial exploring the use of adjuvant pembrolizumab (Keytruda) in cutaneous squamous cell carcinoma (CSCC).

Website:
Twitter:
Facebook:
LinkedIn:

source: https://medinaportal.net

Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Categories:

Leave a Comment